Creating engineered stem cells to enhance immune responses against HIV
Engineering pluripotent stem cells to evade and promote immunity
This study is exploring a way to create special cells that can help your body make antibodies to fight HIV, with the hope of developing new treatments that boost your immune system's ability to tackle the virus.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11001602 on NIH RePORTER |
What this research studies
This research focuses on developing pluripotent stem cells that can be engineered to produce antibodies specifically targeting the HIV virus. By editing these stem cells, researchers aim to create new cell lineages that can differentiate into plasma cells capable of producing these antibodies. The approach involves using advanced techniques to guide the differentiation process and identify new pathways that can enhance the effectiveness of these immune responses. Patients may benefit from innovative therapies that harness the body's own immune system to combat HIV more effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who may benefit from enhanced antibody production.
Not a fit: Patients who are not infected with HIV or those who have advanced stages of AIDS may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve the immune response against HIV.
How similar studies have performed: Other research has shown promise in using engineered stem cells for immune responses, suggesting potential success for this innovative approach.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Sturgeon, Christopher Michael — Icahn School of Medicine at Mount Sinai
- Study coordinator: Sturgeon, Christopher Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.